EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial

Samuel Cortez iD, Dominic Moog, Christopher Lewis, Kelley Williams, Cynthia J Herrick, Melanie E Fields, Teddi Gray, Zhaohua Guo, Ginger Nicol, Thomas Baranski

Journal of the Endocrine Society · 01.07.2024 · 8 (8)

DOI: 10.1210/jendso/bvae108 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Endocrine Society, online erschienen am 12.06.2024. Verfasst von Samuel Cortez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Endocrinology, Diabetes, and Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 6…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A goal of gender-affirming hormone therapy (GAHT) for transgender women is to use estradiol to suppress endogenous production of testosterone. However, the effects of different estradiol regimens and route of administration on testosterone suppression is unknown. This is the first open-label randomized trial comparing different GAHT regimens for optimal estradiol route and dosing.

Objective

To evaluate 1 month and 6 months testosterone suppression <50 ng/dL with pulsed (once- or twice-daily sublingual 17-beta estradiol) and continuous (transdermal 17-beta estradiol) GAHT.

Methods

This study was conducted at an outpatient adult transgender clinic. Thirty-nine transgender women undergoing initiation of GAHT were randomly assigned to receive either once-daily sublingual, twice-daily sublingual, or transdermal 17-beta estradiol. All participants received spironolactone as an antiandrogen. Doses were titrated at monthly intervals to achieve total testosterone suppression <50 ng/dL.

Results

Transdermal 17-beta estradiol resulted in more rapid suppression of total testosterone, lower estrone levels, with no differences in estradiol levels when compared to once-daily and twice-daily sublingual estradiol. Moreover, there was no difference in the mean estradiol dose between the once-daily and twice-daily sublingual 17-beta estradiol group.

Conclusion

Continuous exposure with transdermal 17-beta estradiol suppressed testosterone production more effectively and with lower overall estradiol doses relative to once or twice daily sublingual estradiol. Most transgender women achieved cisgender women testosterone levels within 2 months on 1 or 2 0.1 mg/24 hours estradiol patches. Given no difference between once- or twice-daily sublingual estradiol, pulsed 17-beta estradiol likely provides no benefit for testosterone suppression.

Schlagwörter

Stichwörter der Autor:innen

estradiolgender affirming hormone therapyspironolactonetestosteronetransgender women

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Endocrinology, Diabetes, and Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
  • Washington University School of Medicine in St. Louis, St. Louis,, MO 63110, USA.
  • Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Metabolism, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
  • Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
  • Department of Pediatrics, Division of Hematology/Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
  • Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.

ORCID-Profile: Samuel Cortez

Förderung

  • NCATS NIH HHS

Zitieren

APA

Cortez, S., Moog, D., Lewis, C., Williams, K., Herrick, C. J., Fields, M. E., Gray, T., Guo, Z., Nicol, G., & Baranski, T. (2024). Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial. Journal of the Endocrine Society, 8(8). https://doi.org/10.1210/jendso/bvae108

Vancouver

Cortez S, Moog D, Lewis C, Williams K, Herrick CJ, Fields ME, et al. Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial. Journal of the Endocrine Society. 2024;8(8). doi:10.1210/jendso/bvae108

BibTeX
@article{Cortez2024,
  author = {Cortez, Samuel and Moog, Dominic and Lewis, Christopher and Williams, Kelley and Herrick, Cynthia J and Fields, Melanie E and Gray, Teddi and Guo, Zhaohua and Nicol, Ginger and Baranski, Thomas},
  title = {Effectiveness and Safety of Different Estradiol Regimens in Transgender Females: A Randomized Controlled Trial},
  journal = {Journal of the Endocrine Society},
  year = {2024},
  volume = {8},
  number = {8},
  doi = {10.1210/jendso/bvae108}
}
Kostenlos starten →